GLP-1 Sales Team Staffing: How Companies Are Keeping Up

GLP-1 prescriptions in the United States grew by an estimated 270% between 2021 and 2024. Most pharma commercial teams did not grow by 270%.

That mismatch has created one of the more interesting staffing situations I've seen in pharmaceutical sales: companies with strong products, strong formulary positioning, and no capacity to reach the prescribers who want to write them. Not because of supply constraints — the access story there has improved considerably — but because the field headcount that was appropriate for a niche endocrinology product is nowhere near sufficient for a drug that primary care physicians are now prescribing in volumes comparable to statins.

The companies that have navigated this well have done a few things consistently. The ones that haven't have made predictable mistakes.

The headcount problem nobody planned for

In 2021, GLP-1 sales were specialty-driven. Endocrinologists and obesity medicine specialists were the prescriber universe. Sales teams were sized for that call pattern — tight territories, high-frequency calls on a small prescriber base, relationship-intensive selling.

Then semaglutide's cardiovascular outcomes data expanded the prescriber base by an order of magnitude. Primary care became the volume driver. The prescriber universe for the market leaders went from roughly 15,000 to 20,000 high-priority targets to something closer to 200,000 — and the sales infrastructure was sized for the old market.

The lag between "we need more reps" and "we have more reps in the field" in traditional pharmaceutical hiring is, under favorable conditions, somewhere between four and seven months. You post the role, you recruit, you interview, you background check, you credential, you train, and then you put someone in a car with a sample bag. That process does not compress easily.

Companies that recognized the headcount gap in 2023 and moved immediately were in reasonable shape by mid-2024. Companies that waited for certainty — waiting to see if the CVOT data held, waiting for formulary decisions, waiting for the competitive landscape to clarify — found themselves in 2024 still building a team for a market that had already shifted.

What the companies keeping up are doing

Three approaches account for most of the effective responses I've seen.

Contractor surge teams. The fastest way to add field headcount without the full-cycle hiring delay is a contract sales force deployed alongside an existing team. Experienced pharmaceutical contractors who know primary care call patterns can be deployed in four to six weeks through a contractor marketplace, versus four to seven months for a full-time hire. The trade is cost per rep — contractors with a strong primary care background command a commission-forward structure that's more expensive on a per-call basis than a W-2 rep. The trade makes sense when you're catching up to a market that's moving faster than your HR process can match.

The companies that have done this most effectively treated the contractor team as a genuine field force, not a stopgap. Contractors received the same training, the same call planning support, the same field leadership attention as full-time reps. The ones that treated contractors as a temporary patch with inferior support got inferior results.

Territory redesign before headcount addition. Several companies found they could improve prescriber reach without adding net headcount by redesigning territory geography. Splitting high-density urban territories — in metro markets where a single rep was theoretically covering 8,000 primary care physicians — and adding a rep to handle the second half generated meaningful prescriber reach improvement. This requires that you actually have a rep to deploy to the second territory, which usually means it comes alongside hiring. But the redesign step matters because adding headcount to an oversized territory without redesigning it often just produces two reps covering the same accounts.

Targeted specialty expansion into obesity medicine. The obesity medicine board certification pathway has produced a growing cohort of primary care physicians who've formalized their interest in metabolic disease management. These physicians are high-volume GLP-1 writers, have a receptive posture toward pharmaceutical field contact, and are geographically concentrated in metro areas. Targeted expansion of call plans to identify and prioritize ABOM-certified physicians in existing territories gave some companies meaningful volume growth without expanding their geographic footprint.

The mistakes the laggards made

Four patterns show up repeatedly in companies that fell behind.

Optimizing for headcount quality at the expense of speed. There's a version of GLP-1 staffing that looks like this: a VP of Sales decides that the territory expansion requires people who understand cardiovascular outcomes data deeply, who have obesity medicine relationships, and who can credibly discuss CVOT trial design with cardiologists. That profile exists. It takes five months to recruit and competes with every other pharma company making the same decision. Meanwhile, the primary care prescribers who want to write the product are being called on by the reps of whoever got there first. A B+ rep in the territory in week six beats an A rep in the territory in month five.

Treating training as a prerequisite rather than a parallel track. Standard pharma onboarding puts new reps through a training program before they go into the field. For an urgent territory staffing situation, compressing the training — getting reps into the field with core product knowledge while completing supplementary training in parallel — reduces the time-to-first-call meaningfully. This requires regulatory and medical affairs coordination to define what's required versus supplementary. Companies that treated the full training curriculum as non-negotiable prerequisite added four to six weeks to deployment timelines unnecessarily.

Centralizing territory decisions that should have been made regionally. The prescriber landscape for GLP-1 products varies significantly by geography. Primary care density, insurance mix, formulary status at regional health systems, and obesity medicine program concentration all vary. Companies that required every territory decision — which accounts to prioritize, whether to target a given hospital system's employed primary care network — to clear a central commercial operations team created bottlenecks that slowed field deployment for months.

Using the wrong comp structure for contractors. Independent pharmaceutical contractors are generally not motivated by base salary. They're motivated by commission structure and upside. Companies that offered contract reps a modified version of their W-2 comp plan — low commission rate, high base — attracted reps who wanted a stable paycheck, not the high-performer contractors who would drive results in a challenging market. The contractors who perform in surge situations are typically people who've done this before and know they can make more than the base if given the opportunity.

What this looks like in 2026

The GLP-1 market has matured enough that the pure "get anyone into the territory fast" urgency has subsided at the major players. But three categories of company are still facing versions of the staffing problem.

Smaller specialty pharma companies with GLP-1 or GLP-1-adjacent metabolic products who were too small to build a primary care infrastructure in 2022 and 2023. They're now trying to compete in territories already served by Novo Nordisk and Eli Lilly field forces that have been building prescriber relationships for two years.

Companies launching follow-on agents — including tirzepatide's expanding indications and the next generation of oral GLP-1 agents — who need to move fast into prescriber segments that the market leaders haven't yet fully penetrated.

And biotech companies with combination metabolic products that require both endocrinology and primary care coverage and are trying to build both simultaneously.

For all three, the contractor model isn't a temporary fix. It's a structural part of how you compete in a market where the speed of prescriber penetration determines first-mover advantage.